TickerGuard
Buy Day today: Neutral (59) Mixed market breadth · major macro event coming up
TAK

Takeda Pharmaceutical Co Ltd

Healthcare · Drug Manufacturers - Specialty & Generic · listed since 2008

17.40$ -0.1% vs. previous close Closing price · As of: Aug 13, 2026
🔔 Watch stock
Add to watchlist

Stock Watch

Stock Watch will tell you what changes at Takeda Pharmaceutical Co Ltd.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Price history

Chart

Interactive price chart (TradingView).

52-week range: 13.20 $ to 18.80 $ · Last price: 17.40 $ (As of: August 13, 2026)

Key figures

Key figures at a glance

Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.

Basics

Market Cap ?The value of the entire company on the market: share price times total shares outstanding. 55.5$B
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. –
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. –
Beta ?Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market. –

Performance

Perf. 1M ?Price performance over the last month. 6.00%
Perf. 3M ?Price performance over the last 3 months. 6.80%
Perf. 6M ?Price performance over the last 6 months. -1.40%
YTD Performance (%) ?Price performance since the start of the year (Year to Date). 12.12%
52-Week-High Distance ?How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high. -7.0%
Perf. 1Y ?Price performance over the last 12 months. 22.39%
Perf. 3Y ?Price performance over the last 3 years. 28.59%
Perf. 5Y ?Price performance over the last 5 years. 27.85%
Perf. 10Y ?Price performance over the last 10 years. 16.94%
Perf. Since Inception ?Price performance since the first available trading day (03/06/2008) — with a complete history, that is since the IPO. 50.95%

Technical Indicators

MA 38 Days ?Moving average of the last 38 trading days: the smoothed price path. A price above it signals short-term strength. 16.80$
MA 50 Days ?Moving average of the last 50 trading days — the most widely watched medium-term trend line. 16.50$
MA 200 Days ?Moving average of the last 200 trading days — the dividing line between a long-term uptrend and downtrend. 16.40$
RSI (14) ?Relative Strength Index over 14 days, scale 0 to 100: above 70 counts as overbought, below 30 as oversold. A hint on timing, not a verdict on the company. 57.7
Volatility 30 Days ?Price swings over the last 30 trading days, annualized. The higher the value, the more the price fluctuates. 25.6%
Volatility 250 Days ?Price swings over the last 250 trading days (roughly one market year), annualized. 21.0%

Calculated from the price history · as of 08/14/2026

Valuation

P/E ?Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E. –
Forward P/E ?P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future. –
PEG ?P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey. –
P/B ?Price-to-book ratio: market value relative to book equity. 1.2
P/S ?Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable. –
EV/EBITDA ?Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero. –
Price/FCF ?Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up. –

Profitability

Gross Margin ?Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power. –
EBIT Margin ?EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes. 16.5%
Net Margin ?Net margin: what's left of sales as profit after ALL costs, interest, and taxes. –
Return on Equity ?Return on equity: how much profit does the company generate per year on shareholders' equity? -2.3%
Return on Assets ?Return on assets: how much profit the company generates from its total assets (equity and debt combined). –

Balance Sheet & Safety

Equity Ratio ?Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet. 50.3%
Debt/Equity ?Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity. 0.6
Altman Z″ ?Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks. –
Piotroski ?Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag. 6 out of 9

Growth

Sales Growth Last Quarter ?Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY). 10.20%
EPS Growth Last Quarter ?Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY). -9.80%
Sales Growth (Year) ?Sales growth in the last fiscal year versus the year before. 4.28%
Forward Sales Growth ?Sales growth analysts expect over the next 12 months — an estimate, not a guarantee. -75.66%
Forward EPS Growth ?Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee. –

Dividend

No dividend data is available for this stock yet.

Quality & Screener

Stage ?Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line. –
RS Rating ?Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks. –
EPS Rating ?Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth. –
Fundamental Rating ?Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below. B (60 out of 100)

Comparison

Industry comparison

The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.

Industry: Drug Manufacturers - Specialty & Generic

Industry comparison
Company Market cap ($B) P/E EV/EBITDA Gross Margin % EBIT Margin % Sales Growth (Year) % Perf. 1Y %
Takeda Pharmaceutical Co Ltd TAK 55.5 – – – 16.5 4.3 22.4
Teva Pharma Industries Ltd TEVA 42.5 60.8 – – 4.0 4.3 112.2
Zoetis Inc ZTS 32.0 12.2 9.8 71.8 36.6 2.3 -49.3
United Therapeutics Corporation UTHR 21.3 18.5 11.0 86.6 41.7 10.6 61.9
Viatris Inc VTRS 18.2 – 13.2 39.8 6.8 -3.0 60.2
Neurocrine Biosciences Inc NBIX 15.2 23.8 18.2 64.5 22.8 21.5 14.6
Elanco Animal Health ELAN 11.2 – 22.9 55.1 12.3 6.2 26.4
Dr. Reddy’s Laboratories Ltd RDY 10.3 29.4 – – 4.3 8.6 -12.0
Alkermes Plc ALKS 8.2 57.3 41.9 87.2 -0.2 -5.3 72.7
Median of companies shown 18.2 26.6 15.7 68.2 12.3 4.3 26.4

Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →

Quarters

Quarterly Figures

Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter (JPY m)
2024: Q3 · 1,176,038.0 JPY m Q3 2024: Q4 · 1,144,124.0 JPY m Q4 2025: Q1 · 1,053,400.0 JPY m Q1 2025: Q2 · 1,106,685.0 JPY m Q2 2025: Q3 · 1,112,796.0 JPY m Q3 2025: Q4 · 1,213,211.3 JPY m Q4 2026: Q1 · 1,114,648.9 JPY m Q1 2026: Q2 · 1,219,900.0 JPY m Q2

Source: fundamental data

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales (JPY m) Sales YoY (%) Net Margin (%) OCF (JPY m) FCF (JPY m)
2024: Q3 29.07 287.50 1,176,038 12.70 7.80 280,963 188,511
2024: Q4 0.05 -99.90 1,144,124 3.00 2.10 383,756 327,105
2025: Q1 -0.23 -3,401.50 1,053,400 0.20 -9.80 222,159 129,435
2025: Q2 151.00 78,423.10 1,106,685 -8.40 11.20 215,423 140,355
2025: Q3 -0.03 -100.10 1,112,796 -5.40 -1.10 378,228 325,403
2025: Q4 0.21 339.10 1,213,211 6.00 8.70 373,252 150,879
2026: Q1 -0.74 -226.60 1,114,649 5.80 -2.20 74,528 10,135
2026: Q2 0.48 -99.70 1,219,900 10.20 9.30 127,623 73,812

What Do These Terms Mean?

EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Compare with other stocks →

Outlook

Analysts & Price Target

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Consensus Sell 1 = Strong buy … 5 = Strong sell
Analyst Ratings –
Price Target (average) –
Distance to price –

No price target is available for this stock.

AI classification

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.

How the Rating Is Built

Growth

Growth Score

Ten checks against the annual reports — each one passed counts a point.

3 of 10 Weak growth
  • Revenue grows by more than 15% a year over three years 5.9%
  • More than 10% revenue growth is expected for the coming year -75.7%
  • Share count grows by less than 3% a year 0.7%
  • Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 17.4%
  • Gross margin at 40% or higher and without meaningful erosion 51.1%
  • Goodwill from acquisitions does not grow faster than revenue 37.6%
  • Net debt below twice EBITDA 3.0 x EBITDA
  • Operating cash flow covers the profits of the last three years 2,359,635 m
  • Return on capital at 15% or higher, or up versus two years ago 4.4%
  • Insiders hold at least 10% or are net buyers 0.1%

A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail

Insiders

Insider Transactions

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

Insider Transactions
Date Person Role Type Shares Price Value
Aug 11, 2026 Shannon Elaine Mary Pres., Global Supply & Quality Sell 20,363 17.55 357,371
Aug 10, 2026 Farajallah Awny Samaan Botros Chief Medical Officer Sell 14,006 17.10 239,503
Aug 10, 2026 Ibrahim Ramy Riad Ahmed President, PDT BU Sell 7,277 17.10 124,437
Aug 10, 2026 Pacheco Rhonda Janice President, U.S. Business Unit Sell 16,901 17.10 289,007
Aug 10, 2026 Duprey Lauren Rusckowski Chief Transformation Officer Sell 47,586 17.10 813,721
Aug 10, 2026 Plump Andrew Stewart President, R&D Sell 165,393 17.10 2,828,220
Aug 10, 2026 Pignagnoli Agosti Marcello Head, Strat. & Port. Dev Sell 22,957 17.10 392,565
Aug 10, 2026 Bitetti Teresa Marie President, OBU Sell 50,012 17.10 855,205
Aug 10, 2026 Shannon Elaine Mary Pres., Global Supply & Quality Sell 3,978 17.10 68,024
Aug 10, 2026 Ricci Gabriele Chief Data & Tech. Officer Sell 25,088 17.10 429,005

View all insider transactions →

The company

About the Company

Takeda Pharmaceutical Company Limited befasst sich mit der Erforschung, Entwicklung, Herstellung, Vermarktung und Auslizenzierung pharmazeutischer Produkte. Das Unternehmen bietet Arzneimittel in den Bereichen Gastroenterologie, seltene Erkrankungen, plasmabasierte Therapien, Onkologie, Impfstoffe und Neurowissenschaften an. Es vertreibt seine Produkte unter den Marken Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, Vyvanse/Elvanse, Trintellix und QDENGA. Das Unternehmen unterhält Lizenz- und Kooperationsvereinbarungen zur Entwicklung und Vermarktung von Produkten mit Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology und Nabla Bio. Das Unternehmen ist in Japan, den Vereinigten Staaten, Europa, Kanada, Lateinamerika, China, Asien, Russland/der Gemeinschaft Unabhängiger Staaten, dem Nahen Osten, Ozeanien und Afrika tätig. Das Unternehmen wurde 1781 gegründet und hat seinen Hauptsitz in Chuo, Japan.

IPO Year
2008
ISIN
US8740602052

Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?